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Abstract
Background: JIA-associated uveitis (JIAU) is a serious, sight-threatening disease with significant long-term
complications and risk of blindness, even with improved contemporary treatments. The MIWGUC was set up in
order to propose specific JIAU activity and response items and to validate their applicability for clinical outcome
studies.
Methods: The group consists of 8 paediatric rheumatologists and 7 ophthalmologists. A consensus meeting took
place on November 2015 in Barcelona (Spain) with the objective of validating the previously proposed measures.
The validation process was based on the results of a prospective open, international, multi-centre, cohort study
designed to validate the outcome measures proposed by the initial MIWGUC group meeting in 2012. The meeting
used the same Delphi and nominal group technique as previously described in the first paper from the MIWGUC
group (Arthritis Care Res 64:1365–72, 2012). Patients were included with a diagnosis of JIA, aged less than 18 years,
and with active uveitis or an uveitis flare which required treatment with a disease-modifying anti-rheumatic drug.
The proposed outcome measures for uveitis were collected by an ophthalmologist and for arthritis by a paediatric
rheumatologist. Patient reported outcome measures were also measured.
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Results: A total of 82 patients were enrolled into the validation cohort. Fifty four percent (n = 44) had
persistent oligoarthritis followed by rheumatoid factor negative polyarthritis (n = 15, 18%). The mean uveitis
disease duration was 3.3 years (SD 3.0). Bilateral eye involvement was reported in 65 (79.3%) patients.
The main findings are that the most significant changes, from baseline to 6 months, are found in the AC
activity measures of cells and flare. These measures correlate with the presence of pre-existing structural
complications and this has implications for the reporting of trials using a single measure as a primary
outcome. We also found that visual analogue scales of disease activity showed significant change when
reported by the ophthalmologist, rheumatologist and families.
The measures formed three relatively distinct groups. The first group of measures comprised uveitis activity,
ocular damage and the ophthalmologists’ VAS. The second comprised patient reported outcomes including
disruption to school attendance. The third group consisted of the rheumatologists’ VAS and the joint score.
Conclusions: We propose distinctive and clinically significant measures of disease activity, severity and
damage for JIAU. This effort is the initial step for developing a comprehensive outcome measures for JIAU,
which incorporates the perspectives of rheumatologists, ophthalmologists, patients and families.
Keywords: Anterior uveitis, Uveitis, Juvenile idiopathic arthritis, Response, Damage, Inactive disease,
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Introduction
Juvenile Idiopathic Arthritis (JIA) is the most com-
mon extra-ocular disease associated with childhood
chronic anterior uveitis and has a well-developed
body of internationally agreed case definitions, out-
come measures and disease specific quality of life
metrics that support clinical trials and health eco-
nomic assessments. JIA-associated uveitis (JIAU) is a
serious, sight-threatening disease with significant
long-term complications and risk of blindness even
with improved contemporary treatments [2, 3]. In
contrast to JIA, international consensus on definitions
and management [4, 5], or randomised trials [6], have
only recently been developed in JIAU.
Recent JIA cohorts confirm an annual incidence of
uveitis of 2–4% in the first years after the onset of
arthritis [5, 7] and an estimated cumulative incidence
of 10–20%. JIAU is a rare cause of uveitis in the gen-
eral population and comprises only 1–2% of all cases
of uveitis. Even in tertiary uveitis care settings JIAU
comprises only 4 to 33% of cases [7–11]. The rarity
of JIAU and lack of similarity to more common types
of uveitis has contributed to the scarcity of agreed
terminology and outcome measures Although treat-
ments may simultaneously improve control of both
arthritis and uveitis there is low correlation between
the activity and damage from the two conditions.
Without common measures of treatment effects on
both arthritis and uveitis, trials have been conducted
separately on each organ system, which is an ineffi-
cient use of resources. Understanding the relationship
between treatment effects on both arthritis and uveitis
in JIA may improve patient outcomes and shared care
protocols.
There are now several agreed criteria for judging
the quality of data used in observational studies and
trials. Current evidence for the application of out-
come measures comes from case series, retrospective
studies and heterogeneous populations. Most of the
measures used in JIAU trials do not fulfil the OMER-
ACT (Outcome Measures in Rheumatology) criteria
or COMET (Core Outcome Measures in Effectiveness
Trials) guidelines [13–15]. Published outcomes of
both trials and observational studies remain varied
and studies are rarely designed to replicate, or build
on, previous findings (Mastrangelo et al., submitted
review of outcome measures in this journal) and most
published studies, do not use child-appropriate out-
come measures [12].
The Multinational Interdisciplinary Working Group
for Uveitis in Childhood (MIWGUC) group was set up
in order to address these deficiencies in the quality of as-
sessment and trial design in patients with JIAU [1]. The
sharing of data and results is difficult without standard-
isation of methodology. Even the most important meas-
ure shared as an outcome between doctors patients and
health providers, visual acuity, has a large number of
methods of measurement, which vary by age group, and
whose replicability is highly patient- and operator--
dependent.
The evaluation and management of children with JIAU
requires close collaboration between ophthalmologists
and paediatric rheumatologists, and measures endorsed
by both subspecialties is necessary.
The Standardization of Uveitis Nomenclature (SUN)
Working Group reported a standardized nomenclature
of uveitis, inflammation grading, and outcome measures
[16], providing a validated instrument for comparing
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patient data, in routine clinical practice as well as tri-
als. The SUN criteria are generic and JIAU requires
disease-specific criteria due to its childhood onset, the
lack of an equivalent pattern of uveitis in adults and
the frequent comorbidity of active arthritis. The
MIWGUC group has prioritized reviewing the SUN
criteria to select specific JIAU activity and response
items and validate their applicability for clinical out-
come studies.
The COMET programme emphasises that develop-
ing useful core outcome measures requires both
evidence from carefully controlled short-term rando-
mised trials as well as effectiveness-trials that more
closely resemble routine clinical practice in both the
range of severity of disease and the variety of previ-
ous treatments.
In this study the MIWGUC group reports the re-
sults of a 6 months observational study of JIAU pa-
tients thought by their practitioner to require the
introduction of a new DMARD. The purpose was to
evaluate those measures that were most sensitive to
change following clinically indicated escalation of
treatment and to determine whether a variety of
clinical measures and physician- and patient-reported
evaluations of response and morbidity provided add-
itional, or unique, perspectives on the changes in
disease following treatment escalation.
A consensus statement was developed suggesting
the most relevant domains for future studies. The
range of preferred items provides a framework that
might be used to test more disease-specific patient-re-
lated outcome measures and novel methods of clinical
measurements. In this way we hope to improve the
link between short-term changes appropriate for study
in efficacy trials and the resultant lifelong morbidities
of most relevance to patients and those funding
health interventions.
The wide range of clinical management of JIAU
remains a significant concern for treating rheumatolo-
gists and ophthalmologists and enlarging an evidence-
based consensus between specialists as well as
between specialists and patients is essential to im-
prove outcomes [3, 18].
Methods
Consensus process
The MIWGUC group consists of 8 paediatric rheu-
matologists and 7 ophthalmologists who have a spe-
cial interest in JIAU. A meeting took place on the
19th to 21st of November 2015 in Barcelona (Spain)
with the objective of validating the previously pro-
posed outcome measures [1]. Firstly, the results from
the validation cohort that are reported and discussed
in this paper were presented. The participants then
selected the relevant items to assess uveitis activity,
uveitis damage and responsiveness to treatment over
6 months using a nominal group technique [19]
during the consensus development process. No pa-
tient or patients’ representative participated in the
process.
Patient selection
We conducted an open, international, multi-centre,
prospective cohort study to prospectively validate the
outcome measures proposed by the initial MIWGUC
group meeting in 2009 [1]. Patients (i) with a diagno-
sis of JIA according to the ILAR (International League
of Associations for Rheumatology) classification [20],
(ii) aged less than 18 years, and (iii) presence of active
uveitis at least in one eye (≥ 1+ anterior chamber
(AC) cells grade according the SUN criteria) or uve-
itis flare which required either the initiation of treat-
ment with a conventional synthetic disease-modifying
anti-rheumatic drug (csDMARD) or with a biologic
DMARD (bDMARD) as indicated by the treating
physician for the uveitis. The patients did not to have
to be naive to DMARD treatment.
The patients were assessed by a paediatric rheuma-
tologist and an ophthalmologist at study enrolment,
at 3 months, and 6 months follow-up. Additionally,
patient-reported outcome measures were collected at
each assessment.
Measures
Ophthalmology outcomes
The ophthalmologist documented clinical characteris-
tics of uveitis, onset date, the number of affected eyes
and the anatomical classification of uveitis (anterior,
intermediate, posterior, panuveitis). Uveitis activity
was assessed by slit lamp examination of the anterior
segment and fundoscopy. The following activity mea-
sures were collected for each affected eye: the total
number of AC (anterior chamber) cells, AC cell grade
before and after pupil dilatation (grade 0 (< 1 cells),
grade 0.5+ (1–5 cells), 1+ (6–15 cells), 2+ (16–25
cells), 3+ (26–50 cells), 4+ (> 50 cells)), AC flare
grade according to the SUN and MIWGUC criteria
[1, 16], and visual acuity. The laser flare photometry
values were added when available. The MIWGUC cri-
teria for flare have less response categories (no flare,
moderate, intense, not possible) compared to the
SUN criteria (no flare, faint, moderate, marked, in-
tense, not possible). Visual acuity was documented by
a logMAR (logarithm of the minimum angle of reso-
lution) chart. Structural eye complications and current
topical eye treatment were also entered by the oph-
thalmologist. The ophthalmologist assessed the overall
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uveitis activity on a visual analogue scale (VAS, range
0 to 100 mm, 0 = inactive disease).
Rheumatology outcomes
The paediatric rheumatologist reported clinical JIA pa-
rameters: age at onset, disease duration, the number of
joints with active arthritis, treatment with csDMARDs
and bDMARDs, concomitant treatment with systemic
glucocorticoids and non-steroidal anti-inflammatory
drugs (NSAIDs) as well as overall disease activity on a
VAS (range 0 to 100 mm, 0 = inactive disease).
Patient-related outcomes
The parents reported the days of hospitalization due to
uveitis, lost days in kindergarten or school and restric-
tions in daily activities due to uveitis for the last 6
months. The assessment of overall well-being was
assessed by families on a VAS (range 0 to 100 mm, 0 =
best possible value). Functional complications were
assessed by the Childhood Health Assessment Question-
naire (CHAQ, range 0–3, 0 = no functional limitations
[21]) and quality of life by the Paediatric Quality of Life
Inventory (PedsQL, range 0–100, 100 = best possible
quality of life [22]). A summary of the measures is
shown in Table 1.
Statistics
Parameters that were related to JIA disease characteris-
tics and the patient reported outcomes were reported at
the patient level, whereas parameters that were related
to uveitis were reported at the eye level. The sensitivity
to change within the 6 months observation period was
investigated by linear mixed models. The change in each
parameter was estimated between baseline to 3-months
follow-up, baseline to 6-months follow-up and 3-months
to 6-months follow-up within a linear mixed model. The
number of affected eyes was additionally included as
cluster variable in the analyses on the eye level. Pre-
liminary analyses suggested that there was no select-
ive loss to follow-up in our study. Linear mixed
models result in reliable effect estimates in the pres-
ence of missing data and non-selective drop-out [23].
The association between all the considered parameters
were studied by linear mixed models including the
eye level as a cluster variable within the patient level
using the patient identification number. All statistical
analyses were conducted with STATA 12.1 (Stata-
Corp. 2011. Stata Statistical Software: Release 12.
College Station, TX: StataCorp LP). P values less than
0.05 were considered significant.
Results
Patient characteristics
A total of 82 patients were recruited in 10 study cen-
tres between January 2013 and June 2015. Sixty pa-
tients (73%) completed follow up at 6-months by the
paediatric rheumatologist and the ophthalmologist.
There was no statistically significant difference in
socio-demographic and clinical characteristics at base-
line between patients with and without 6 months fol-
low-up except for the age at JIA onset (3.4 years, SD
2.6 versus 5.5 years, SD 4.7). The patient reported
outcome measures were only available for 51 patients
(62% of 82) at baseline and for 32 patients (39%) at
the 6 months follow-up due to administrative reasons.
The baseline characteristics of the study sample are
shown in Tables 2 and 3.
The mean age for the 82 patients was 8.9 years (SD
3.7) at study inclusion. Approximately three out of
Table 1 Summary of tested outcome measures in the prospective study in patients with JIAU. Summary of tested outcome
measures in the international, multi-centre, prospective, and uncontrolled cohort study as proposed by Heiligenhaus et al. [14]
Paediatric Rheumatologist
• Physician ‘ s global assessment of disease
activity on a visual analogue scale , 0-100
• Number of joints with active arthritis
Ophthalmologist
• Total number of AC cells
• AC cell grade before and after dilatation
• ACflare grade according to the SUN criteria
and MIWGUC criteria
• Ophthalmologists global assessment of
uveitis activity on a visual analogue scale, 0-100
• Visual acuity, LogMAR
• Presence of structural complications
– Ocular hypotony (IOP ≤ 6 mmHg)
– Ocular hypertension
– Posterior synechiae formation
– Glaucoma
– Cataract
– Band keratopathy in the cornea
– Optic disc edema
– Macular edema
– Epiretinal membrane formation
– Vitreous haze
Patient‘s reported outcome
• Overall well-being on a visual analogue scale, 0-100
• Functional ability by C-HAQ
• Quality of life by PedsQL
• Days of hospitalizations due to uveitis
• Lost days in kindergarden or school due to uveitis
• Days with restrictions in daily life due to uveitis
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four patients were female and 77 (94%) were Cauca-
sian. More than half of the patients (n = 44, 54%) had
persistent oligoarthritis followed by rheumatoid factor
(RF) negative polyarthritis (n = 15, 18%). Sixty (73%)
patients were anti-nuclear antibody (ANA) positive.
The mean JIA and uveitis disease duration was 4.8 (SD
3.8) and 3.3 years (SD 3.0) years at baseline, respect-
ively. Bilateral eye involvement was reported for 65
(79.3%) of the patients at baseline resulting in 147 eyes
with uveitis. All patients had an active uveitis (AC cell
grade above 0) in at least one eye at baseline.
All patients were treated with a DMARDs at base-
line, 85.3% with a csDMARD (methotrexate 75.5%,
azathioprine 14.7%) and 67.7 with a bDMARD (adali-
mumab 35.3%, infliximab 20.6%, tocilizumab 11.8%).
32.4% were treated with csDMARD only, 14.7% with
a bDMARD only and 52.9% with a combination of a
csDMARD and bDMARD.
Table 2 Sociodemographic and clinical characteristics of
enrolled patients. Sociodemographic and clinical characteristics
of the patients at study enrolment
Total
sample
N = 82
Female sex 62 (75.6%)
ANA positive 60 (73.1%)
HLA-B27 positive 8 (9.8%)
Rheumatoid factor positive 7 (8.5%)
Clinical JIA Characteristics (n = 82)
Oligoarthritis, persistent 44 (53.7%)
Oligoarthritis, extended 9 (11.0%)
RF- Polyarthritis 15 (18.3%)
Psoriatic arthritis 1 (1.2%)
Enthesitis-related arthritis 4 (4.9%)
Undifferentiated JIA 4 (4.9%)
Unknown* 5 (6.1%)
JIA disease duration, years, mean (SD) 4.8 (3.8)
Age at disease onset in years, mean (SD) 3.8 (3.2)
Physician’s global, VAS, mean (SD) (range 0–100) 34.0 (28.7)
Patient reported outcomes (n = 51)
Number of days in hospital due to uveitis in the
last 6 months
12 (23.5%)
Missed days in kindergarten/ school due to uveitis
in the last 6 months
27 (52.9%)
Number of days with restrictions in daily life due to
uveitis in the last 6 months
12 (23.5%)
Patients assessment of overall well-being, VAS,
mean (SD) (range 0–100)
34.1 (29.7)
C-HAQ, mean (SD) (range 0–3) 0.81 (1.04)
PedsQL, mean (SD) (range 0–100) 78.7 (21.5)
Clinical Uveitis Characteristics (n = 82)
Uveitis disease duration, years, mean (SD) 3.3 (3.0)
Age at uveitis onset in years, mean (SD) 5.1 (2.9)
Number of affected eyes
unilateral 17 (20.7%)
bilateral 65 (79.3%)
Physician’s global, VAS, mean (SD) 44.3 (34.1)
Number of patients with at least one active eye
(AC cell grade > 0)
82
(100.0%)
AC anterior chamber, ANA anti-nuclear antibody, CHAQ Childhood Health
Assessment Questionnaire, HLA human leukocyte antigen, PedsQL Paediatric
Quality of Life Inventory, RF rheumatoid factor, SD standard deviation, VAS
visual analogue scale range 0 to 100.
* The category unknown includes patients with JIA for which the category was
not reported by the paediatric rheumatologist.
Table 3 Clinical characteristics of eyes with uveitis. Clinical
characteristics of uveitis on eye level at enrolment
N = 147 affected
eyes
AC cell grade (number of cells per hpf)
according to SUN examined after dilatation
0 [< 1] 30 (20.4%)
0.5+ [1–5] 16 (10.9%)
1+ [6–15] 53 (36.1%)
2+ [16–25] 26 (17.7%)
3+ [26–50] 9 (5.1%)
4+ [> 50] 2 (1.4%)
Missing 11 (7.5%)
Visual acuity, logMAR, mean (SD) 0.48 (0.51)
logMAR ≥0.1 (≤ 20/50) 79 (66.4%)
logMAR ≥1 (≤ 20/200) 5 (4.2%)
Any structural complication 81 (56.3%)
Ocular hypotony 3 (2.1%)
Ocular hypertension 6 (4.3%)
Posterior synechiae 60 (43.2%)
Glaucoma 6 (4.4%)
Cataract 28 (19.9%)
Band keratopathy 31 (21.5%)
Optic disc edema 10 (10.9%)
Macular edema 14 (21.5%)
Epiretinal membrane formation 7 (11.3%)
Vitreous haze, mean (SD) 1.37 (0.92)
Other complications 12 (12.8%)
Concomitant ocular uveitis treatment
Previous subtenon / intraocular steroid
injections
2 (1.4%)
Topical corticosteroid medication 76 (51.7%)
Glaucoma medication 10 (6.8%)
AC anterior chamber, LogMAR logarithm of the minimum angle of resolution,
SD standard deviation, VAS visual analogue scale
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Sensitivity to change between baseline and 6-months
follow-up
Sensitivity to change between baseline and the 6-months
follow-up was assessed to identify the parameters that
may change after starting treatment. The detailed results
were reported in Table 4.
Ophthalmologic outcomes
The global assessment of uveitis activity on VAS by
the ophthalmologist, the number of AC cells and the
AC cell grade improved during the 6-months follow-
up. There were significant improvements in AC flare
grade at the 6-months follow-up. Visual acuity did
not significantly improve (LogMAR baseline: mean =
0.48 (SD 0.51), LogMAR 3-months follow-up: mean =
0.42 (SD 0.52), beta = − 0.05, 95%CI: − 0.10; 0.001)
during the study period. The number of eyes with
impaired vision (≤20/50) improved slightly over the
6 months (79 (66.4%) of 119 eyes at baseline, 52
(60.5%) of 86 eyes at 6-months follow-up, p = 0.447).
The decrease was more pronounced in eyes without
glaucoma or macular edema, but also not statistically
significant (64 (64.0%) of 100 eyes at baseline, 43
(56.6%) of 76 eyes at 6-months follow-up).
Structural complications were found in 81 eyes (56.3%
of 144 reported) at baseline and for 64 eyes (62.1% of
103) at 6-months follow-up (Fig. 1). There was no sig-
nificant change in the frequency of eyes with structural
complications overall or for any single complication over
the 6 months.
The change in specific complications over time was in-
vestigated in 60 patients (103 eyes) with available 6-
months follow-up data. Patients who were not included
in the analyses (22 patients, 44 eyes) did not significantly
differ in respect to uveitis disease characteristics and ac-
tivity from the entire sample. However, the excluded pa-
tients showed a lower rate of structural complications at
baseline (n = 17, 39%). In patients who could be investi-
gated for 6-months, 64 (62.8%) eyes had at least one
structural complication at baseline which persisted at
the 6months follow up (Fig. 1 and Table 5). New poster-
ior synechiae formation was reported in 3 eyes (2.9%), a
new cataract in 6 eyes (5.8%) and new vitreous haze in 5
eyes (4.9%) at 6- months follow-up. Optic disc edema
(n = 7, 6.8%), ocular hypotony (IOP ≤ 6 mmHg, n = 2,
2.9%) and ocular hypertension (IOP (Intraocular pres-
sure)) ≥ 21mmHg, n = 2, 2.9%) reported at baseline was
no longer reported at 6- months follow-up. More de-
tailed information about the change in structural com-
plications was reported in Table 5.
Rheumatological outcomes
The global assessments of JIA disease activity by the
paediatric rheumatologist significantly improved. This
improvement could be observed mainly in the first 3
months (beta = − 17.7, 95%CI: − 23.3; − 12.1 for change
between baseline and 3-months follow-up; beta = − 2.5,
95%CI: − 8.5; 3.4 for change between 3-months and 6-
months follow-up). A total of 21 patients (25.6%) had at
least one joint with active arthritis at baseline. The num-
ber of joints with active arthritis and the proportion of
patients with at least one active joint did not signifi-
cantly change.
Patient reported outcomes
Patient reports of overall well-being improved signifi-
cantly from baseline levels. Functional ability (C-HAQ,
beta = −.34, 95%CI: − 0.61; − 0.07) and quality of life
(PedsQL, beta = 7.2, 95%CI: 2.1; 12.3) improved steadily
over the 6 months. The number of missed days in kin-
dergarten or school (beta = − 4.3, 95%CI: − 7.3; − 1.3) as
well as the number of days with restrictions in daily life
due to the uveitis (beta = − 5.9, 95%CI: − 11.4; − 0.4) sig-
nificantly decreased at 6 and 3months, respectively.
There was no change in the number of hospital visits.
Association of uveitis anterior chamber activity and
structural complications
The presence of structural complications was associ-
ated with AC cell grade and AC flare grade (Table 6).
The strength of association between AC cell and flare
grade was mediated by the presence of structural
complications. At baseline, among eyes without any
structural complications the AC flare grade was “no
flare” in 81% of the eyes with an AC cell grade of
zero and in 29% of the eyes with an AC cell grade
greater or equal to one. In contrast, among eyes with
at least one structural complication the AC flare
grade was “no flare” in 46% of the eyes with an AC
cell grade of zero and in 13% in eyes with an AC cell
grade greater than zero. Similar results were found if
posterior synechiae were the only complication
considered.
Association of subjective meassures and quality of life and
functional assessments
The uveitis activity parameters such as the ophthalmolo-
gist’s global assessment of uveitis activity, number of AC
cells and the AC cell grade were positively associated
among themselves (Fig. 2 and Additional file 1: Table
S1). The VAS measures all correlated, the strongest was
between the rheumatologist and patients’ assessment
and the weakest between the ophthalmologist and pa-
tients’ assessment. The ophthalmologist VAS was most
associated with AC activity and structural complications.
It was more associated with visual acuity than the
rheumatologist VAS. The rheumatologist VAS was most
associated with the joint score as well as the patient-
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Table 4 Change in parameters between baseline and 6-months follow-up. Change in parameters that are associated with JIA
(paediatric rheumatologist) and uveitis (ophthalmologist) and patient reported outcome measures from baseline to 6-months
follow-up (bold highlighted beta/ OR were statistically significant)
Baseline 3-
months
follow-up
6-
months
follow-up
Change between
Baseline and 3-months
follow-up
Change between
Baseline and 6-months
follow-up
Change between 3-
months and 6-months
follow-up
Effect
Size
Baseline
to 6-
months
follow-
up
n; mean
(sd),
median
n; mean
(sd),
median
n; mean
(sd),
median
beta/ OR p value
95% CI
beta/ OR p value
95% CI
beta/ OR p value
95% CI
n(%)a n(%)a n(%)a
Analyses on patient level
n = 82 n = 77 n = 64
Pediatric rheumatologist
Physician’s global about
JIA disease activity, VAS, 0–
100
71; 34.0
(28.7); 30
64; 17.0
(22.6); 10
57; 13.4
(22.4); 5
−17.7 < 0.001–23.29;
−12.14
−20.2 < 0.001–26.09;
−14.41
−2.5 0.401–8.46; 3.38 0.66
Number of joints with
active arthritis
83; 0.6
(1.5); 0
77; 0.4
(1.5); 0
64; 0.9
(3.8); 0
−0.1 0.636–0.77; 0.47 0.3 0.313–0.32; 1.00 0.5 0.152–0.18; 1.15 0.10
Patients reported outcomes
Overall well-being; VAS;
0–100
47; 34.1
(29.7); 26
43; 23.5
(20.3); 20
30; 23.2
(22.3); 12
−10.5 0.003–17.48;
−3.62
−13.1 0.001–20.93;
−5.27
− 2.6 0.524–10.39; 5.29 0.41
C-HAQ, 0–3 35; 0.81
(1.04); 0.5
27; 0.69
(0.88); 0.5
18; 0.52
(0.59);
0.44
− 0.2 0.056–0.45; 0.01 − 0.3 0.014–0.61; −
0.07
−0.1 0.4–0.39; 0.16 0.13
PedsQL, 0–100 52; 78.7
(21.5);
87.8
40; 81.7
(17.9);
86.9
26; 85.5
(13.5);
89.7
3.8 0.088–0.57; 8.21 7.2 0.006 2.08; 12.30 3.4 0.201–1.80; 8.54 0.15
Number of days in hospital
due to uveitis
40; 1.9
(6.0); 0
32; 0.7
(2.7); 0
19; 1.1
(4.2); 0
−1.2 0.274–3.33; 0.94 −0.7 0.561–3.26; 1.77 0.4 0.736–2.16; 3.06 0.25
Missed days in
kindergarden/ school due
to uveitis
51; 4.8
(6.7); 1
47; 3.2
(9.2); 0
32; 0.5
(1.6); 0
−1.7 0.211–4.30; 0.95 −4.3 0.004–7.25; −
1.34
−2.6 0.085–5.61; 0.37 0.20
Number of days with
restrictions in daily life due
to uveitis
39; 7.4
(16.9); 0
32; 1.7
(4.8); 0
19; 5.0
(10.6); 0
−5.9 0.037–11.40; −
0.36
−2.7 0.417–9.25; 3.83 3.2 0.355–3.55; 9.90 0.44
Analyses on eye level
n = 147 n = 132 n = 103
Ophthalmologist
Physician’s global about
disease activity in the eyes,
VAS, 0–100
113; 45.2
(33.9); 50
111; 30.6
(33.5); 20
87; 25.2
(32.3); 14
−15.0 < 0.001–19.13;
− 10.83
−20.0 < 0.001–24.57;
− 15.44
− 5.0 0.029–9.55; −
0.51
0.43
Total number of AC cells 46; 7.4
(6.4); 7.5
28; 1.4
(3.2); 0
33; 1.9
(4.8); 0
−4.9 < 0.001–6.99; −
2.79
− 5.0 < 0.001–7.03; −
2.91
−0.1 0.942–2.29; 2.12 1.10
Visual acuity, logMAR 119; 0.48
(0.51); 0.3
101; 0.39
(0.50); 0.1
86; 0.42
(0.52);
0.11
−0.1 0.015–0.11; −
0.01
−0.1 0.062–0.10; 0.00 0.0 0.727–0.04; 0.06 0.18
AC cell grade 136; 2.81
(1.25); 3
116; 1.81
(1.20); 1
93; 1.39
(0.82); 1
−1.0 < 0.001–1.26; −
0.80
−1.5 < 0.001–1.72; −
1.22
−0.4 0.001–0.69; −
0.19
0.81
AC flare grade (no flare
versus flare), SUN
99
(70.2%)
49
(38.6%)
24
(25.3%)
0.1 < 0.001 0.03; 0.21 0.0 < 0.001 0.01; 0.08 0.3 0.006 0.12; 0.71 0.67
AC flare grade (no flare
versus flare), MIWGUC
53
(61.6%)
31
(37.4%)
17
(25.8%)
0.1 < 0.001 0.03; 0.34 0.0 < 0.001 0.01; 0.14 0.3 0.032 0.09; 0.90 0.50
Any structural
complications
81
(56.3%)
73
(56.2%)
64
(62.1%)
0.9 0.867 0.27; 2.99 1.1 0.904 0.28; 4.28 1.2 0.79 0.30; 4.77 0.01
Ocular hypotony 3 (2.1%) 3 (2.4%) 0 (0.0%) b b b 0.02
Ocular hypertension 6 (4.3%) 8 (6.5%) 4 (4.1%) 6.2 0.235 0.31; 124.32 0.2 0.321 0.01; 4.05 0.0 0.109 0.00; 2.06 0.09
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reported outcome measures, especially the CHAQ score.
The patients’ VAS was most associated with ocular dam-
age as well as the patients’ functional ability and quality
of life measures.
Consensus about meausures for uveitis activity and
damage
The definition of a response and damage index as
well as the definition of uveitis remission and inactive
disease was part of the second part of the meeting.
The consensus process was based on the results of
the prospectively followed uveitis patients within this
study as reported in the first part of the results
section.
The following items were selected for defining re-
sponse to treatment
 Slit lamp evaluation:
○ Total number of anterior chamber cells (AC)
○ AC cells before pupil dilatation
 Grade of AC flare according to SUN criteria
 New Occurrence and course of inflammation-
related structural complications:
○ Occurrence of new posterior synechia
○ Change of optic disc edema
○ Change of macular edema
○ Change of vitreous haze
 Ophthalmologist’s global assessment of uveitis
activity in the worst eye assessed on a VAS score
ranging between 0 to 100 mm
 Paediatric rheumatologist’s global assessment of
disease activity assessed on a VAS score ranging
between 0 to 100 mm
 Parents' (for patients < 8 years)/ patients rating
about any problems with the eye assessed on a VAS
score ranging between 0 to 100 mm
Table 4 Change in parameters between baseline and 6-months follow-up. Change in parameters that are associated with JIA
(paediatric rheumatologist) and uveitis (ophthalmologist) and patient reported outcome measures from baseline to 6-months
follow-up (bold highlighted beta/ OR were statistically significant) (Continued)
Baseline 3-
months
follow-up
6-
months
follow-up
Change between
Baseline and 3-months
follow-up
Change between
Baseline and 6-months
follow-up
Change between 3-
months and 6-months
follow-up
Effect
Size
Baseline
to 6-
months
follow-
up
n; mean
(sd),
median
n; mean
(sd),
median
n; mean
(sd),
median
beta/ OR p value
95% CI
beta/ OR p value
95% CI
beta/ OR p value
95% CI
n(%)a n(%)a n(%)a
Posterior synechiae 60
(43.2%)
60
(46.2%)
53
(52.0%)
5.7 0.23 0.33; 96.67 4.7 0.324 0.21; 104.42 0.8 0.903 0.05; 15.33 0.06
Glaucoma 6 (4.4%) 6 (5.1%) 5 (5.4%) b b b 0.03
Cataract 28
(19.9%)
23
(18.3%)
24
(23.5%)
b b b 0.04
Band keratopathy 31
(21.5%)
31
(24.6%)
27
(26.7%)
25.6 0.067 0.80; 826.75 14.8 0.132 0.44; 493.90 0.6 0.716 0.03; 11.13 0.07
Optic disc edema 10
(10.9%)
6 (7.0%) 3 (4.8%) b b b 0.11
Macular edema
(Funduscopy)
9 (7.0%) 4 (5.0%) 2 (2.9%) 0.3 0.288 0.04; 2.68 0.2 0.195 0.02; 2.14 0.7 0.811 0.06; 9.42 0.07
Macular edema (OCT) 14
(21.5%)
4 (12.5%) 2 (6.1%) b b b 0.08
Epiretinal membrane
formation (Funduscopy)
7 (5.5%) 7 (8.5%) 4 (5.9%) b b b 0.12
Epiretinal membrane
formation (OCT)
7 (11.3%) 7 (17.5%) 5 (14.3%) b b b 0.11
Vitreous haze (yes/no) 15
(16.3%)
15
(18.3%)
13
(19.1%)
1.6 0.518 0.38; 6.97 1.5 0.632 0.31; 6.75 0.9 0.89 0.20; 4.11 0.06
Other complications 12
(12.8%)
2 (2.4%) 0 (0.0%) b b b 0.10
beta regression coefficient for continuously distributed variables, CI confidence interval, n number of patients with valid assessment in the reported parameter, OR
Odds ratio for categorical variables, sd standard deviation
apercentages refer to the number of patients or eyes with valid assessments in the considered parameter
bnot estimable due to the low number of complications
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Fig. 1 Proportion of eyes with structural complication. Proportion of eyes with any structural complication and specific structural complications
(baseline n = 147 eyes, 3-months follow-up n = 132 eyes, 6-months follow-up n = 103 eyes)
Table 5 Change in structural complication between baseline and 6-months follow-up. Change in structural complication within the
6 months follow-up
Baseline 3-months follow-up 6-months follow-up
Changes in structural complications
between baseline and 3-months
follow-up
Changes in structural complications
between baseline and 6-months
follow-up
(n = 103
eyes)
(n = 103 eyes) (n = 103 eyes)
total total newly
reported
no longer
reported
total newly
reported
no longer
reported
N % N % N % N % N % N % N %
Any structural complication 64 62.8 61 61.6 64 62.1
Ocular hypotony (IOP≤ 6 mmHg) during the last 3 months 3 2.9 3 2.9 1 1.0 1 1.0 0 0.0 0 0.0 3 2.9
Ocular hypertension (IOP≥ 21 mmHg) during the last 3 months 6 5.8 6 5.8 2 1.9 2 1.9 4 3.9 1 1.0 3 2.9
Posterior synechiae formation 50 48.5 51 49.5 1 1.0 0 0.0 53 51.5 3 2.9 0 0.0
Glaucoma 4 3.9 3 2.9 0 0.0 1 1.0 5 4.9 1 1.0 0 0.0
Cataract 18 17.5 17 16.5 2 1.9 3 2.9 24 23.3 6 5.8 0 0.0
Band keratopathy in the cornea 25 24.3 25 24.3 2 1.9 2 1.9 26 22.9 2 1.9 0 0.0
Optic disc edema 10 9.7 6 5.8 0 0.0 4 3.9 3 2.9 0 0.0 7 6.8
Macular edema 10 9.7 5 4.9 2 1.9 7 6.8 3 2.9 1 1.0 8 7.8
Epiretinal membrane formation 5 4.9 5 4.9 0 0.0 0 0.0 5 4.9 0 0.0 0 0.0
Vitreous haze 14 13.6 13 12.6 4 3.9 5 4.9 13 12.6 5 4.9 6 5.8
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 Parents' (for patients < 8 years)/ patients rating
about the course of uveitis during the last 3 months
on a Likert scale (better / something better/ stable/
something worst/ worst)
 Parents (for patient’s age of under 8 years)/ patients
rating about improvement under uveitis treatment
during the last 3 months assessed on a VAS score
ranging between 0 to 100 mm
 Change in health related quality of life, e.g. by the
PedsQL, EYEQL …
 Missed work/school /kindergarten days due of the
uveitis
Remission in JIAU on medication or off medication,
analogous to the Wallace criteria for JIA [24], is defined
by fulfilling the following conditions for at least 6
Table 6 Association of AC cell grade and AC flare grade. Association of AC cell grade and AC flare grade in eyes with and without
any structural complication
All eyes Eyes with at least one structural
complications
Eyes with no structural complications
AC cell grade AC cell grade AC cell grade
0 0.5+ 1+ 2+/ 3+/
4+
0 0.5+ 1+ 2+/ 3+/
4+
0 0.5+ 1+ 2+/ 3+/
4+
Baseline
AC flare grade: no
flare
20
(66.7%)
5
(31.3%)
9
(17.0%)
7 (18.9%) 6
(46.2%)
2
(25.0%)
3
(10.3%)
3 (12.0%) 13
(81.3%)
3
(37.5%)
6
(25.0%)
4 (33.3%)
AC flare grade: any
flare
10
(33.3%)
11
(68.8%)
44
(83.0%)
30
(81.1%)
7
(53.8%)
6
(75.0%)
26
(89.7%)
22
(88.0%)
3
(18.8%)
5
(62.5%)
18
(75.0%)
8 (66.7%)
3-months follow-up
AC flare grade: no
flare
56
(83.6%)
6
(30.0%)
2
(14.3%)
2 (16.7%) 23
(82.1%)
4
(26.7%)
2
(18.2%)
2 (22.2%) 33
(84.6%)
2
(40.0%)
0 (0.0%) 0 (0.0%)
AC flare grade: any
flare
11
(16.4%)
14
(70.0%)
12
(85.7%)
10
(83.3%)
5
(17.9%)
11
(73.3%)
9
(81.8%)
7 (77.8%) 6
(15.4%)
3
(60.0%)
3
(100.0%)
3
(100.0%)
6-months follow-up
AC flare grade: no
flare
60
(87.0%)
1
(12.5%)
2
(33.3%)
0 (0.0%) 33
(82.5%)
1
(16.7%)
0 (0.0%) 0 (0.0%) 27
(93.1%)
0 (0.0%) 2
(66.7%)
0 (0.0%)
AC flare grade: any
flare
9
(13.0%)
7
(87.5%)
4
(66.7%)
4
(100.0%)
7
(17.5%)
5
(83.3%)
3
(100.0%)
4
(100.0%)
2 (6.9%) 2
(100.0%)
1
(33.3%)
0 (0.0%)
All patients had active uveitis at baseline in at least one eye. Among all eyes that are affected with uveitis were 20 eyes inactive and had no flare at baseline
Fig. 2 Summary of association of parameters that were assessed by the ophthalmologist, paediatric rheumatologist and patients. Association of
parameters that were assessed by the ophthalmologist, paediatric rheumatologist and patients (‘+++’ = positively associated, p < 0.001; ‘++’ =
positively associated, p < 0.01; ‘+’ = positively associated, p < 0.05; ‘---’ = negatively associated, p < 0.001; ‘--’ = negatively associated, p < 0.01; ‘-’ =
negatively associated, p < 0.05; ‘x’ not significantly associated). Details are shown in Additional file 1: Table S1
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months on medication, or inactive disease for > 3
months after discontinuation of all anti-inflammatory
treatments for uveitis, respectively. In addition, inactive
uveitis is defined by fulfilling the following conditions at
a specific assessment. It is required that both eyes fulfil
the following conditions
 Slit lamp total number of AC cells: 0 inflammatory
cells. In aphakia patients some cells may be present
in the anterior vitreous
 Absence of optic disc oedema
 Absence of macular oedema
 Absence of vitreous haze (< 0.5 +)
 Ophthalmologist global assessment of uveitis activity
on VAS score ranging between 0 to 100mm must be 0
The following items assess uveitis-related damage
either in the right or left eye. The following compli-
cations define damage: visual acuity, synechiae, cata-
ract, maculopathy, optic disc edema, decreased visual
acuity, ocular hypertension (> 21 mmHg), ocular hy-
potony (< 6 mmHg), glaucomatous field loss and /or
glaucomatous optic atrophy, band keratopathy, epiret-
inal membrane formation. Additionally, uveitis-related
decreased visual acuity, visual deterioration of less
than 0.3 in any eye, uveitis related disability reported
by the ophthalmologist measured on a VAS ranging
between 0 to 100 mm, uveitis related disability re-
ported by the paediatric rheumatologist measured on
a VAS ranging between 0 to 100 mm.
Discussion
This study reports multiple outcomes of a representative
population of patients with JIAU in a 6-month period fol-
lowing clinically-driven initiation of new DMARD treat-
ment. The main findings are that the most significant
changes, from baseline to 6months, are found in the AC
activity measures of cells and flare. These measures correl-
ate with the presence of pre-existing structural complica-
tions and this has implications for the reporting of trials
using a single measure as a primary outcome.
We also found that visual analogue scales of activity
showed significant change when reported by the ophthal-
mologist, rheumatologist and families. The measures
formed three relatively distinct groups. The first com-
prised uveitis activity and ocular damage and the ophthal-
mologists’ VAS. The second comprised patient-reported
outcomes which included disruption to school attendance.
The third consisted of the rheumatologists’ VAS, joint
score and patient-reported outcomes.
There have been recent trials of adalimumab in JIAU
using AC flare and an increase in AC cells as primary
endpoints as well as a health economic analysis using
visual acuity and surgical interventions as markers of
health utility [6, 25, 26]. The variety of endpoints used
in adult non-anterior uveitis, and the problems that arise
from non-compatible studies has already been remarked
upon [27, 28] and the same problem exists with chronic
anterior uveitis in childhood [12]. In this study we con-
firm that AC cells are the most sensitive measure to
change with onset of treatment that, with present know-
ledge, clinicians believe to be of most benefit in reducing
the patients’ loss of function and quality of life caused by
the disease. It also suggests that the three areas of AC
cells and flare, patient reported functioning and quality
of life and joint assessment should provide relatively sep-
arate areas of assessing the benefits of new treatments.
Although the primary aim of treatments is to reduce
the rate of irreversible visual loss, this study emphasises
the relatively minor value that changes in visual acuity
have in the short-term assessment of change with
treatment.
Standardized outcome measures of the lifelong out-
come of JIAU are crucial. The SUN criteria [16] was
used in the first clinical trial in paediatric uveitis, which
led to the approval of a adalimumab for JIA associated
uveitis [6], but formally it has not been validated. In
addition few studies measure the impact of uveitis from
a patient and parents perspective, as there is only one
paediatric uveitis-specific quality of life assessment [18]
for US-English speaking patients. A further deficit is the
lack of disease specific measures of visual function, and
generic measures of visual function used in trials of
adults with macular disease or glaucoma may not ad-
equately capture the range of visual disturbance found
in JIAU including the high rates of amblyopia which cre-
ate a disparity between ocular damage and patients-re-
ported visual symptoms and function. Adults with good
binocular vision prior to visual damage will have a much
lower threshold for noticing visual symptoms and will
suffer more from loss of binocular macular function
than children with amblyopia developing early in the
disease process.
Our group proposed a Paediatric Uveitis Outcome
Measure (PROMS) in 2012 [1] in the present paper we
have started validation by providing empirical evidence
of those measures sensitive to change and how PROMS
relate to indicators thought clinically relevant as prog-
nosticators of lifelong disability. The importance of in-
cluding patient and parent perspectives to capture the
overall impact of disease [17], as well as the physicians’
global assessment of the disease activity has been shown
by the significant size of these changes over time, and
their relative independence from other metrics.
The introduction of the routine use of the ophthalmol-
ogist’s clinical judgment as a gold standard, through a
visual analogue score for addressing inflammatory activ-
ity and severity of uveitis has problems. However, the
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strong correlation between the ophthalmologist global
assessment and several clinical and instrumental vari-
ables (i.e. arthritis activity, laser flare photometry values)
seems to assess the need to consider including the oph-
thalmologist’s perspective. This is now routine in several
paediatric rheumatologic diseases where the rheumatolo-
gist’s global activity score is a recognised part of the ac-
tivity assessment [29, 30]. The correlation of arthritis
activity with the ophthalmologic global assessment is of
interest as uveitis activity from clinical observation, does
not seem to correlate with arthritis activity. The activity
of joint disease will obviously influence the nature of the
ophthalmic consultation and influence decisions about
systemic management.
We have demonstrated multiple measures that
demonstrate sensitivity to change over a clinically
relevant period of time. Recent efficacy and health
economic and drug efficacy studies have used add-
itional measures and different time scales – it might
be helpful to construct a single measure for all pur-
poses such as the JADAS (Juvenile Arthritis Disease
Activity Score) scoring systems in JIA. A construct of
“uveitis inflammatory activity” “UVEDAI”, for adult
uveitis has been proposed, and some items used in
this study are identical such as anterior chamber cell
grade, vitreous haze, macula edema and patient-re-
ported evaluations [31]. It does not include severity
and damage items or a patient/parent global assess-
ment. A comprehensive disease measure that is able
to assess, at the same time and over the time, the
overall picture of uveitis, combining both severity as
well as activity, is still lacking.
Our finding that the primary measures of activity
are mediated by coexisting damage confirm the clin-
ical feeling that drug efficacy is unlikely to be the
same in all eyes and therefore stratification by dis-
ease damage is likely to be necessary to obtain the
best measure of drug efficacy. Although there are
some situations where simplification such as a single,
numeric disease score, is useful, there are other clin-
ical situations where the complexity of the clinical
course of JIAU is unavoidable and multiple measures
will always be needed for an individualised assess-
ment Evaluation of their relative weighting and re-
dundancy is now required to minimise data
collection for future targeted treatments.
We have also proposed definitions for treatment effi-
cacy; remission, inactive disease and damage for JIAU.
What remains most difficult to determine is the level
and length of remission that is adequate to predict the
two major outcomes of relevance to patients: the time of
lifelong remission, and the elimination of risk of future
visual loss. We intend to validate these outcomes in the
frame of the MIWGUC working group.
Our study had some limitations. The patient reported
outcomes were not available for all patients at enrolment
and in follow-up due to administrative reasons. There-
fore, the analyses may lack of statistical power. In
addition, there were a considerable number of patients
lost to follow-up in our study. However, we did not find
that the missing data biased the results. We also did not
include patient or carer participation at this stage of the
process.
This work is the initial step for developing a compre-
hensive assessment of outcomes of children with JIAU
which incorporates the perspectives of rheumatologists,
ophthalmologists, patients and families. We propose
measures of disease activity, severity and damage. A
standardized method to assess the clinical characteristics
of the disease will also serve as a useful tool to compare
JIAU patients children within and between clinical trials.
Conclusion
We propose measures of disease activity, severity and
damage based on our prospective validation study of
our previously proposed outcome measures [14]. This
work is the initial step for developing a comprehen-
sive outcome measures for JIAU, that incorporate the
perspectives of rheumatologists, ophthalmologists, pa-
tients and families.
Additional file
Additional file 1: Table S1. Associations parameters. Associations
between parameters that are associated to JIA and uveitis and patient
reported outcomes (bold highlighted beta/ OR were statistically
significant). (DOCX 30 kb)
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